Table 2. Randomized control trials of combination drugs.
*Due to the vast number of ongoing trials, trials in this chart are limited to those with >1000 participants
NCT ID: National Clinical Trial Identifier; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
| Intervention | NCT ID | No. of participants* | Duration | Phase | Sponsor |
| Combination drugs | |||||
| Drug: hydroxychloroquine + intravenous famotidine | NCT04370262 | 1170 | April 2020– April 2021 | Phase 3 | Northwell Health |
| Drug: thiazide or thiazide-like diuretics; drug: calcium channel blockers; drug: ACE inhibitor; drug: angiotensin receptor blocker | NCT04330300 | 2414 | March 2020– March 2021 | Phase 4 | National University of Ireland, Galway, Ireland |
| Drug: lopinavir/ritonavir; drug: hydroxychloroquine sulfate; drug: losartan; drug: placebos | NCT04328012 | 4000 | April 2020–April 2021 | Phase 2, phase 3 | Bassett Healthcare |
| Drug: remdesivir; drug: lopinavir/ritonavir; drug: interferon beta-1A; drug: hydroxychloroquine; other: standard of care | NCT04315948 | 3100 | March 2020–March 2023 | Phase 3 | Institut National de la Santé Et de la Recherche Médicale, France |
| Drug: lopinavir/ritonavir; drug: hydroxychloroquine; drug: remdesivir | NCT04330690 | 2900 | March 2020–May 2022 | Phase 2 | Sunnybrook Health Sciences Centre |
| Biological: convalescent anti-SARS-CoV-2 plasma; drug: sarilumab; drug: baricitinib; drug: hydroxychloroquine; other: injective placebo; other: oral placebo | NCT04345289 | 1500 | May 2020–June 2021 | Phase 3 | Thomas Benfield |
| Drug: lopinavir-ritonavir; drug: corticosteroid; drug: hydroxychloroquine; drug: azithromycin; biological: convalescent plasma; drug: tocilizumab | NCT04381936 | 12000 | March 2020–June 2021 | Phase 2, phase 3 | University of Oxford |
| Drug: hydroxychloroquine sulfate tablets; drug: lopinavir/ritonavir oral tablet; drug: hydroxychloroquine sulfate tablets plus lopinavir/ritonavir oral tablets; drug: placebo | NCT04403100 | 1968 | June 2020–November 2020 | Phase 3 | Cardresearch |
| Drug: hydroxychloroquine; drug: azithromycin | NCT04334382 | 1550 | April 2020–December 2021 | Phase 3 | Intermountain Health Care, Inc. |
| Drug: hydroxychloroquine; drug: azithromycin (Azithro); drug: placebo for hydroxychloroquine; drug: placebo for azithromycin | NCT04358068 | 2000 | May 2020–March 2021 | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug: hydroxychloroquine; drug: placebo oral tablet | NCT04318444 | 1600 | March 2020–March 2022 | Phase 2, phase 3 | Columbia University |
| Drug: favipiravir (3200 mg + 1200 mg); drug: favipiravir (3600 mg + 1600 mg); drug: favipiravir (3200 mg + 1200 mg) combined with hydroxychloroquine; drug: favipiravir (3200 mg + 1200 mg) combined with azithromycin; drug: hydroxychloroquine; drug: hydroxychloroquine combined with azithromycin | NCT04411433 | 1000 | May 2020–July 2020 | Phase 3 | Ministry of Health, Turkey |
| Drug: hydroxychloroquine - daily dosing; drug: hydroxychloroquine - weekly dosing | NCT04341441 | 3000 | April 2020–April 2021 | Phase 3 | Henry Ford Health System |
| Drug: hydroxychloroquine | NCT04363827 | 2300 | May 2020–March 2021 | Phase 2 | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori |
| Drug: hydroxychloroquine sulfate; drug: ascorbic acid | NCT04328961 | 2000 | March 2020–October 2020 | Phase 2, phase 3 | University of Washington |
| Drug: hydroxychloroquine; drug: placebo oral tablet | NCT04334148 | 15000 | April 2020–July 2020 | Phase 3 | Adrian Hernandez |
| Drug: emtricitabine/tenofovir disoproxil; drug: hydroxychloroquine; drug: placebo: emtricitabine/tenofovir disoproxil placebo; drug: placebo: hydroxychloroquine | NCT04334928 | 4000 | April 2020–July 2020 | Phase 3 | Plan Nacional sobre el Sida (PNS) |
| Drug: hydroxychloroquine; drug: placebo | NCT04325893 | 1300 | April 2020–September 2020 | Phase 3 | University Hospital, Angers |
| Drug: hydroxychloroquine; drug: placebo oral tablet | NCT04421664 | 1500 | March 2020–August 2020 | Phase 3 | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Dietary supplement: vitamins; drug: hydroxychloroquine; drug: imatinib; drug: favipiravir; drug: telmisartan | NCT04356495 | 1057 | July 2020–January 2021 | Phase 3 | University Hospital, Bordeaux |
| Drug: hydroxychloroquine; other: placebo | NCT04308668 | 3000 | March 2020–May 2020 | Phase 3 | University of Minnesota |
| Other: placebo; drug: remdesivir; drug: baricitinib | NCT04401579 | 1032 | May 2020–August 2023 | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) |